KPRX

Kiora Pharmaceuticals, Inc. (KPRX) ESG Analysis Analysis (2026)

Invetso Score: 5.7/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.2 (Moderate)

KPRX appears to have limited disclosed environmental intensity metrics, which reduces transparency versus larger peers that typically report emissions, energy, and waste data.

The provided zero R&D-to-revenue metric suggests a lighter operating footprint, but peer comparison is constrained because many healthcare peers disclose more complete environmental programs.

Low leverage can indirectly support environmental investment flexibility, yet it does not itself indicate stronger environmental management versus peers.

Absent evidence of material environmental controversies in the supplied data, KPRX looks broadly in line with smaller-cap peers, though disclosure depth remains thinner.

Social

Score:

KPRX’s limited disclosed social metrics make workforce, patient, and community oversight harder to assess versus peers with more extensive ESG reporting.

The zero stock-based compensation-to-revenue metric may indicate lower dilution pressure, but it does not directly demonstrate stronger employee or stakeholder practices than peers.

For a healthcare company, social materiality usually centers on product safety, access, and compliance, and the supplied data provides no peer-leading evidence on those factors.

Overall social positioning appears average to slightly below better-disclosed peers because transparency is limited rather than because of identified adverse social incidents.

Governance

Score:

KPRX’s very low debt-to-equity ratio suggests conservative capital structure, which can reduce creditor pressure and support governance flexibility versus more leveraged peers.

Net debt to EBITDA below one indicates manageable balance-sheet risk, a positive governance signal relative to peers with heavier refinancing or covenant exposure.

However, the supplied metrics do not show board independence, audit quality, or shareholder-rights practices, leaving governance assessment less complete than for better-disclosed peers.

Overall governance looks somewhat better than highly levered small-cap peers, but the absence of core governance disclosures prevents a stronger relative score.

Overall Score

Score:

KPRX’s ESG positioning is moderate versus peers, with a modest governance edge from low leverage offset by limited disclosure across environmental and social dimensions.

Score Driver: Low Leverage Supports Relative Governance Resilience, But Sparse ESG Disclosure Limits Evidence Of Stronger Overall Positioning.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Kiora Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →